ahlam1399
06-08-2015, 09:24 PM
Sa**fi says diabetes drug on track to be resubmitted to U.S. FDA in Q3
PARIS, June 8 (Reuters) - Sa**fi said on Monday that it was on track to resubmit an application for authorisation of its lixisenatide drug for the treatment of type 2 diabetes to the U.S. Food and Drug Administration (FDA) in the third quarter.http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/470b7ec3/sc/21/mf.gif?resize=1%2C1
http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=teuWMNDarNY:VIN27zfRoSM:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=teuWMNDarNY:VIN27zfRoSM:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=teuWMNDarNY:VIN27zfRoSM:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=teuWMNDarNY:VIN27zfRoSM:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=teuWMNDarNY:VIN27zfRoSM:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/teuWMNDarNY
PARIS, June 8 (Reuters) - Sa**fi said on Monday that it was on track to resubmit an application for authorisation of its lixisenatide drug for the treatment of type 2 diabetes to the U.S. Food and Drug Administration (FDA) in the third quarter.http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/470b7ec3/sc/21/mf.gif?resize=1%2C1
http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=teuWMNDarNY:VIN27zfRoSM:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=teuWMNDarNY:VIN27zfRoSM:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=teuWMNDarNY:VIN27zfRoSM:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=teuWMNDarNY:VIN27zfRoSM:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=teuWMNDarNY:VIN27zfRoSM:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/teuWMNDarNY